Health Condition 1: C159- Malignant neoplasm of esophagus, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: NIL: NIL
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: Adult patients aged 18 to 80 years with histologically confirmed carcinoma esophagus who are planned to undergo neoadjuvant chemotherapy or chemoradiotherapy followed by radical esophagectomy will be eligible for inclusion in the study.
Exclusion criteria
Exclusion criteria: Patients with ECOG performance status not greater than 2 those found to have inoperable or unresectable disease during surgery and patients with poor-quality or unavailable CT imaging will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association between preoperative sarcopenia and short-term postoperative morbidity following radical esophagectomy for carcinoma esophagus.Timepoint: During index hospitalization until discharge At 30 days post-surgery At 90 days post-surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Prevalence of sarcopenia among patients undergoing radical esophagectomyTimepoint: Before surgery after completion of neoadjuvant therapy;Association between systemic inflammatory markers & postoperative complicationsTimepoint: From surgery until 30 days after surgery;Combined predictive value of sarcopenia & systemic inflammatory markers for postoperative complicationsTimepoint: From surgery until 30 days after surgery;Length of intensive care unit stayTimepoint: During index hospital admission until discharge from intensive care unit;Duration of postoperative mechanical ventilator supportTimepoint: During index hospital admission;Length of postoperative hospital stayTimepoint: At hospital discharge;Severity of postoperative complications assessed using Clavien Dindo classificationTimepoint: At hospital discharge;Thirty day postoperative mortalityTimepoint: Thirty days after surgery;Ninety day postoperative mortalityTimepoint: Ninety days after surgery;Change in skeletal muscle index & hand grip strength following neoadjuvant therapyTimepoint: Assessed at baseline before neoadjuvant therapy & repeated before surgery after completion of neoadjuvant therapy | — |
Countries
India
Contacts
Public ContactDr Abhijit Talukdar
Dr Bhubaneswar Borooah Cancer Institute
Outcome results
None listed